Apotex Can't Sink Amgen's IP Suit Over Drugs To Aid Chemo
By Danielle Nichole Smith ( April 5, 2019, 8:54 PM EDT) -- Amgen can move forward with allegations that Apotex infringed a patent covering its chemotherapy-easing drugs Neupogen and Neulasta after a Florida federal judge ruled that it was too early to find the suit was barred by litigation over a related patent....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.